Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors

Bioorg Chem. 2023 Feb:131:106331. doi: 10.1016/j.bioorg.2022.106331. Epub 2022 Dec 19.

Abstract

In order to develop novel inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the UDP binding site of the enzyme, a series of aldotetronic acid-based hydroxamic acids was accessed in chiral pool syntheses starting from 4,6-O-benzylidene-d-glucose and l-arabinitol. The synthesized hydroxamic acids were tested for LpxC inhibitory activity in vitro, revealing benzyl ether 17a ((2S,3S)-4-(benzyloxy)-N,3-dihydroxy-2-[(4-{[4-(morpholinomethyl)phenyl]ethynyl}benzyl)oxy]butanamide) as the most potent LpxC inhibitor. This compound was additionally tested for antibacterial activity against a panel of clinically relevant Gram-negative bacteria, bacterial uptake, and susceptibility to efflux pumps. Molecular docking studies were performed to rationalize the observed structure-activity relationships.

Keywords: Aldotetronic acid derivatives; Antibiotics; Bacterial uptake; LasB; LpxC inhibitors; Molecular-docking studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidohydrolases* / antagonists & inhibitors
  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacology
  • Bacteria / metabolism
  • Binding Sites
  • Enzyme Inhibitors* / chemistry
  • Enzyme Inhibitors* / pharmacology
  • Escherichia coli*
  • Hydroxamic Acids / chemistry
  • Hydroxamic Acids / pharmacology
  • Molecular Docking Simulation
  • Structure-Activity Relationship

Substances

  • Amidohydrolases
  • Anti-Bacterial Agents
  • Enzyme Inhibitors
  • Hydroxamic Acids
  • UDP-3-O-acyl-N-acetylglucosamine deacetylase